Pre-made Retifanlimab benchmark antibody ( Whole mAb, anti-PDCD1/PD-1 therapeutic antibody, Anti-CD279/PD1/SLEB2/hSLE1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Retifanlimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Retifanlimab, designated as INCMGA 0012, is a humanised IgG4k anti-PD-1 monoclonal antibody, being developed by Incyte Corporation, under a license from.
| Products Name (INN Index) | Pre-Made Retifanlimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody |
|---|---|
| INN Name | Retifanlimab |
| Target | PDCD1 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Preregistration |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | MacroGenics,Incyte Corporation,ZAI Lab |
| Conditions Approved | NA |
| Conditions Active | Gastic cancers,Oesophageal cancer,Anal cancer,Endometrial cancer,Merkel cell carcinoma,Solid tumours,Colorectal cancer,Acute myeloid leukaemia,Squamous cell cancer,Non-small cell lung cancer,Glioblas |
| Conditions Discontinued | Haematological malignancies |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | PDCD1 |
| Package |
